Reine Lifescience Cited for Adulterated APIs

Drug GMP Report
A A
The FDA hit API manufacturer Reine Lifescience with a warning letter for significant GMP violations observed during a November inspection of its facility in Gujurat, India.

To View This Article:

Login

Subscribe To Drug GMP Report